JP7284830B2 - タンパク質チロシンホスファターゼ阻害剤 - Google Patents

タンパク質チロシンホスファターゼ阻害剤 Download PDF

Info

Publication number
JP7284830B2
JP7284830B2 JP2021558566A JP2021558566A JP7284830B2 JP 7284830 B2 JP7284830 B2 JP 7284830B2 JP 2021558566 A JP2021558566 A JP 2021558566A JP 2021558566 A JP2021558566 A JP 2021558566A JP 7284830 B2 JP7284830 B2 JP 7284830B2
Authority
JP
Japan
Prior art keywords
mmol
tert
butyl
dihydrospiro
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527796A5 (https=
JP2022527796A (ja
Inventor
エフ．ブレイク ジェイムズ
ローレンス ボーイズ マーク
ジョセフ チカレッリ マーク
ダブリュ．クック アダム
エス．エー．エルセイド モハメッド
ブラッドフォード フェール ジェイ
ピー．フィッシャー ジョン
ジェイ ヒンクリン ロナルド
ジャン ユートン
ティー．マックナルティ オーレン
ジェイ．メヒア マセドニオ
イー．ロドリゲス マーサ
イー．ウォン クリスティーナ
Original Assignee
アレイ バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ インコーポレイテッド filed Critical アレイ バイオファーマ インコーポレイテッド
Publication of JP2022527796A publication Critical patent/JP2022527796A/ja
Publication of JP2022527796A5 publication Critical patent/JP2022527796A5/ja
Priority to JP2023049681A priority Critical patent/JP2023078421A/ja
Application granted granted Critical
Publication of JP7284830B2 publication Critical patent/JP7284830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021558566A 2019-04-02 2020-03-30 タンパク質チロシンホスファターゼ阻害剤 Active JP7284830B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023049681A JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828356P 2019-04-02 2019-04-02
US62/828,356 2019-04-02
US202062992558P 2020-03-20 2020-03-20
US62/992,558 2020-03-20
PCT/IB2020/053019 WO2020201991A1 (en) 2019-04-02 2020-03-30 Protein tyrosine phosphatase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023049681A Division JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2022527796A JP2022527796A (ja) 2022-06-06
JP2022527796A5 JP2022527796A5 (https=) 2022-09-02
JP7284830B2 true JP7284830B2 (ja) 2023-05-31

Family

ID=70277430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558566A Active JP7284830B2 (ja) 2019-04-02 2020-03-30 タンパク質チロシンホスファターゼ阻害剤
JP2023049681A Pending JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023049681A Pending JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Country Status (26)

Country Link
US (3) US11634417B2 (https=)
EP (1) EP3947367A1 (https=)
JP (2) JP7284830B2 (https=)
KR (1) KR102698608B1 (https=)
CN (1) CN113874363B (https=)
AU (1) AU2020251841B2 (https=)
BR (1) BR112021018664A2 (https=)
CA (1) CA3135555C (https=)
CL (2) CL2021002542A1 (https=)
CO (1) CO2021013030A2 (https=)
CR (1) CR20210501A (https=)
CU (1) CU20210080A7 (https=)
DO (1) DOP2021000206A (https=)
EC (1) ECSP21072994A (https=)
GE (2) GEP20237561B (https=)
IL (2) IL320682A (https=)
MA (1) MA55511A (https=)
MX (1) MX2021012122A (https=)
PE (1) PE20220141A1 (https=)
PH (1) PH12021552227A1 (https=)
PY (1) PY2018672A (https=)
SG (1) SG11202110502PA (https=)
TW (1) TWI766261B (https=)
UY (1) UY38628A (https=)
WO (1) WO2020201991A1 (https=)
ZA (1) ZA202108443B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078421A (ja) * 2019-04-02 2023-06-06 アレイ バイオファーマ インコーポレイテッド タンパク質チロシンホスファターゼ阻害剤

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
BR112021005733A2 (pt) 2018-10-17 2021-07-27 Array Biopharma Inc. inibidores de proteína tirosina fosfatase
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
US20240025924A1 (en) * 2021-03-23 2024-01-25 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2022206684A1 (zh) * 2021-03-31 2022-10-06 南京明德新药研发有限公司 一系列含Se的吡嗪类化合物及其应用
US20240190843A1 (en) * 2021-04-01 2024-06-13 Array Biopharma Inc. Crystalline form of a shp2 inhibitor
CN117460725A (zh) * 2021-04-01 2024-01-26 阵列生物制药公司 Shp2抑制剂的晶型
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技（上海）有限公司 Shp2磷酸酶抑制劑的製備及其應用
CN115960109B (zh) * 2021-05-31 2024-06-25 药雅科技(上海)有限公司 稠环类shp2磷酸酶抑制剂的制备及其应用
TW202319056A (zh) 2021-07-09 2023-05-16 南韓商治納輔醫藥科技有限公司 Ｓｈｐ２抑制劑及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4417600A4 (en) * 2021-10-14 2025-02-19 Beijing Tide Pharmaceutical Co., Ltd. SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CN119095836A (zh) * 2022-03-23 2024-12-06 Array生物制药公司 Shp2抑制剂的结晶盐形式
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
EP4735452A2 (en) 2023-06-30 2026-05-06 Merck Patent GmbH Heterobifunctional compounds for the degradation of kras protein
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502994A (ja) 2014-01-17 2017-01-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP2018517752A (ja) 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
TW201408658A (zh) 2012-08-27 2014-03-01 Array Biopharma Inc 絲胺酸／酥胺酸激酶抑制劑
EP3053923B1 (en) 2013-09-30 2018-04-11 Korea Research Institute of Chemical Technology Triazolopyrazine derivatives as tyrosin kinase inhibitors
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
EP3630770B1 (en) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
JP7447002B2 (ja) 2017-09-11 2024-03-11 クルーゾン・ファーマシューティカルズ・インコーポレイテッド ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
AU2019240299B2 (en) 2018-03-21 2023-06-22 D.E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
US12138263B2 (en) 2018-03-21 2024-11-12 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
CN112601750B (zh) 2018-08-10 2023-10-31 纳维尔制药有限公司 Ptpn11（shp2）抑制剂
US20210393623A1 (en) * 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
BR112021005733A2 (pt) 2018-10-17 2021-07-27 Array Biopharma Inc. inibidores de proteína tirosina fosfatase
CU20210080A7 (es) * 2019-04-02 2022-05-11 Array Biopharma Inc Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502994A (ja) 2014-01-17 2017-01-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JP2018517752A (ja) 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JORGE GARCIA FORTANET; ET AL，ALLOSTERIC INHIBITION OF SHP2: IDENTIFICATION OF A POTENT, SELECTIVE, AND ORALLY 以下備考，JOURNAL OF MEDICINAL CHEMISTRY，2016年07月12日，VOL:59, NR:17，PAGE(S):7773-7782，http://dx.doi.org/10.1021/acs.jmedchem.6b00680，EFFICACIOUS PHOSPHATASE INHIBITOR
PAOLA CIAPETTI; ET AL，CHAPTER 15 - MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS，THE PRACTICE OF MEDICINAL CHEMISTRY，NL，ELSEVIER，2008年，PAGE(S):290-342，http://dx.doi.org/10.1016/B978-0-12-374194-3.00015-9

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078421A (ja) * 2019-04-02 2023-06-06 アレイ バイオファーマ インコーポレイテッド タンパク質チロシンホスファターゼ阻害剤

Also Published As

Publication number Publication date
KR20210146389A (ko) 2021-12-03
IL286462A (en) 2021-10-31
JP2023078421A (ja) 2023-06-06
AU2020251841B2 (en) 2025-01-30
US11884664B2 (en) 2024-01-30
MX2021012122A (es) 2021-11-03
AU2020251841A1 (en) 2021-10-07
CN113874363B (zh) 2024-11-12
CL2024000183A1 (es) 2024-06-07
CR20210501A (es) 2021-11-02
CN113874363A (zh) 2021-12-31
PY2018672A (es) 2021-09-24
IL320682A (en) 2025-07-01
KR102698608B1 (ko) 2024-08-27
EP3947367A1 (en) 2022-02-09
GEAP202315746A (en) 2023-07-10
US20220251083A1 (en) 2022-08-11
CL2021002542A1 (es) 2022-06-24
GEP20237561B (en) 2023-10-25
UY38628A (es) 2020-10-30
WO2020201991A1 (en) 2020-10-08
CA3135555C (en) 2023-09-19
CA3135555A1 (en) 2020-10-08
CO2021013030A2 (es) 2021-10-20
DOP2021000206A (es) 2021-11-21
US20240124453A1 (en) 2024-04-18
BR112021018664A2 (pt) 2021-11-23
ECSP21072994A (es) 2021-11-18
US11634417B2 (en) 2023-04-25
JP2022527796A (ja) 2022-06-06
MA55511A (fr) 2022-02-09
PE20220141A1 (es) 2022-01-27
US20200317665A1 (en) 2020-10-08
TW202102490A (zh) 2021-01-16
TWI766261B (zh) 2022-06-01
PH12021552227A1 (en) 2022-05-30
CU20210080A7 (es) 2022-05-11
ZA202108443B (en) 2023-04-26
SG11202110502PA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7284830B2 (ja) タンパク質チロシンホスファターゼ阻害剤
US12187721B2 (en) Protein tyrosine phosphatase inhibitors
JP6878615B2 (ja) Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
KR101961500B1 (ko) 세린/트레오닌 키나제 억제제
RU2799449C2 (ru) Ингибиторы протеинтирозинфосфатазы
RU2780532C1 (ru) Ингибиторы протеинтирозинфосфатазы
EA047856B1 (ru) Ингибиторы протеинтирозинфосфатазы
HK40057282A (en) Protein tyrosine phosphatase inhibitors
CN117486888B (en) Tricyclic compounds and uses thereof
OA20546A (en) Protein tyrosine phosphatase inhibitors.
HK40057282B (zh) 蛋白质酪氨酸磷酸酶抑制剂
HK40062341A (en) Protein tyrosine phosphatase inhibitors
EA047802B1 (ru) Ингибиторы протеинтирозинфосфатазы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220818

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230327

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230327

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230404

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230405

C272 Notice of ex officio correction

Free format text: JAPANESE INTERMEDIATE CODE: C272

Effective date: 20230405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230519

R150 Certificate of patent or registration of utility model

Ref document number: 7284830

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150